Source link : https://newshealth.biz/health-news/nsclc-survival-benefit-seen-with-egfr-tki-chemo/
Median PFS benefit was just over 3 months in patients with EGFR-mutant NSCLC who had tumor suppressor gene co-mutations. Medscape Medical News Source link : https://www.medscape.com/viewarticle/nsclc-survival-benefit-seen-egfr-tki-chemo-2025a1000nlj?src=rss Author : Publish date : 2025-09-07 23:35:00 Copyright for syndicated content belongs to the linked Source.
The post NSCLC Survival Benefit Seen With EGFR-TKI + Chemo first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-07 23:35:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8